295 related articles for article (PubMed ID: 35002699)
21. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
23. Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H interaction.
Chiu HC; Huang WR; Liao TL; Chi PI; Nielsen BL; Liu JH; Liu HJ
J Biol Chem; 2018 Aug; 293(32):12542-12562. PubMed ID: 29907572
[TBL] [Abstract][Full Text] [Related]
24. Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.
Zhang J; Su G; Lin Y; Meng W; Lai JKL; Qiao L; Li X; Xie X
Discov Med; 2019 Jan; 27(146):27-36. PubMed ID: 30721649
[TBL] [Abstract][Full Text] [Related]
25. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Chen WJ; Chang CY; Lin JK
Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
[TBL] [Abstract][Full Text] [Related]
26. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity.
Henri P; Prevel C; Pellerano M; Lacotte J; Stoebner PE; Morris MC; Meunier L
Br J Dermatol; 2020 Mar; 182(3):678-689. PubMed ID: 31145809
[TBL] [Abstract][Full Text] [Related]
27. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
28. Cytometry of cyclin proteins.
Darzynkiewicz Z; Gong J; Juan G; Ardelt B; Traganos F
Cytometry; 1996 Sep; 25(1):1-13. PubMed ID: 8875049
[TBL] [Abstract][Full Text] [Related]
29. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K; Burris Rd HA; Yap TA; Hamilton E; Rugo HS; Goldman JW; Dann S; Liu F; Wong GY; Krupka H; Shapiro GI
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1105-1124. PubMed ID: 34176404
[No Abstract] [Full Text] [Related]
30. Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation.
Poon RY; Toyoshima H; Hunter T
Mol Biol Cell; 1995 Sep; 6(9):1197-213. PubMed ID: 8534916
[TBL] [Abstract][Full Text] [Related]
31. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.
Akli S; Keyomarsi K
Cancer Biol Ther; 2003; 2(4 Suppl 1):S38-47. PubMed ID: 14508079
[TBL] [Abstract][Full Text] [Related]
32. From simple to complex patterns of oscillatory behavior in a model for the mammalian cell cycle containing multiple oscillatory circuits.
Gérard C; Goldbeter A
Chaos; 2010 Dec; 20(4):045109. PubMed ID: 21198121
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
[TBL] [Abstract][Full Text] [Related]
34. B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.
Tanguay D; Pavlovic S; Piatelli MJ; Bartek J; Chiles TC
J Immunol; 1999 Sep; 163(6):3160-8. PubMed ID: 10477583
[TBL] [Abstract][Full Text] [Related]
35. Cyclin dependent kinases in cancer: potential for therapeutic intervention.
Canavese M; Santo L; Raje N
Cancer Biol Ther; 2012 May; 13(7):451-7. PubMed ID: 22361734
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
37. Control of the G1/S transition.
Reed SI
Cancer Surv; 1997; 29():7-23. PubMed ID: 9338094
[TBL] [Abstract][Full Text] [Related]
38. New functional activities for the p21 family of CDK inhibitors.
LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E
Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657
[TBL] [Abstract][Full Text] [Related]
39. The Renaissance of Cyclin Dependent Kinase Inhibitors.
Ettl T; Schulz D; Bauer RJ
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053461
[TBL] [Abstract][Full Text] [Related]
40. Current concepts in neuro-oncology: the cell cycle--a review.
Dirks PB; Rutka JT
Neurosurgery; 1997 May; 40(5):1000-13; discussion 1013-5. PubMed ID: 9149259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
